Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Digestive System Diseases

Gland and Hormone Related Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Prostatic Neoplasms

Breast Neoplasms

Syndrome

Esophageal Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Urinary Bladder Neoplasms

Thyroid Neoplasms

Thyroid Diseases

Carcinoma, Renal Cell

Facies

Head and Neck Neoplasms

Solitary Pulmonary Nodule

Sarcoma

Histiocytoma, Malignant Fibrous

Mesothelioma

Mesothelioma, Malignant

Liposarcoma

Osteosarcoma

Mouth Neoplasms

Carcinosarcoma

Mixed Tumor, Mullerian

Chondrosarcoma

Fibrosarcoma

Histiocytoma

Carcinoma, Bronchogenic

Hemangiosarcoma

Kidney Neoplasms

Carcinoma, Small Cell

Leiomyosarcoma

Phyllodes Tumor

Hemangioma

Adenoma, Pleomorphic

Parathyroid Neoplasms

Otorhinolaryngologic Neoplasms

Pancoast Syndrome

Adenosarcoma

Lymphangiosarcoma

Myosarcoma

Mixed Tumor, Mesodermal

Tracheal Neoplasms

Facial Neoplasms

Esophageal Cancer

Ovarian Cancer

Ovarian Epithelial Cancer

Renal Cell Carcinoma

Soft Tissue Sarcoma

Malignant Mesothelioma

Oral Cancer

Malignant Mixed Mullerian Tumor

All Drugs and Chemicals

Antineoplastic Agents

Androgens

Fluorouracil

Belinostat

Parathyroid Hormone

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Histone Deacetylase Inhibitors

Enzyme Inhibitors

300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1

belinostat

250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.

5-Fluorouracil (5-FU)

Topotarget A/S

This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors

Valerio Therapeutics

Diseases and Abnormalities at or Before Birth

Wounds and Injuries

Nervous System Diseases

Birth Injuries

Craniocerebral Trauma

Head Injuries, Penetrating

Trauma, Nervous System

Infant, Newborn, Diseases

Wounds, Penetrating

Micronutrients

Silicon

Patient receives prosthetic made from CPE then the SOC, silicon.

Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.

Chlorinated polyethylene elastomer

Sudarat Kiat-amnuay, DDS MS

Mark S Chambers, DMD MS

James D Anderson, DDS MScD

Lawrence Gettleman, DMD, MSD

The purpose of this study is to evaluate a new rubber material used to make prosthetic replacements of the face lost to cancer, trauma, or birth defects.

Maxillofacial prosthetics is a subspecialty of prosthodontics, providing the clinical rehabilitation treatment of patients who have lost parts of the face due to cancer, trauma, or birth defects. It is an orphan field that:

* treats few patients, making the subspecialty unprofitable for manufacturers to develop new materials;
* offers fundamental rehabilitation and improvement in the quality of life to patients who may have exhausted personal or third party funding; and
* provides a dental solution to an essentially medical problem.

Silicone rubber materials have been used for facial rehabilitation for more than 4 decades with few improvements. There is a clear need for new, alternative, and more economic materials for extraoral maxillofacial prostheses. Research at Gulf South Research Institute in New Orleans by the Principal Investigator and others in the 1970s and 1980s developed an alternative low-cost thermoplastic industrial rubber material (chlorinated polyethylene, CPE) that met all toxicological (safety) and physical (effectiveness) requirements. A Phase 2 clinical trial at the time yielded equivocal results when compared to conventional but costly silicone rubber products.

This research is a controlled, randomized, single-crossover, double-blinded investigator-initiated multicenter Phase 3 clinical trial treating 100 patients that evaluates:

* experimental thermoplastic CPE; and
* control silicone (Silastic Adhesive A/MDX4-4210) materials for non-inferiority of CPE based on functional and subjective characteristics, and on the quality of life.

The clinical centers of the trial are at M.D. Anderson Cancer Center in Houston, Texas, and at the Toronto Sunnybrook Regional Cancer Centre in Toronto, Canada.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors	NCT00413322	Tumor	belinostat 5-Fluorouracil ...	18 Years -	Valerio Therapeutics
Clinical Trial of New Elastomer for Maxillofacial Prosthetics	NCT00123097	Facial Neoplasm... Head and Neck N... Head Injuries, ... Birth Injuries	Chlorinated pol...	21 Years -	University of Louisville

Spots Global Cancer Trial Database for facial neoplasms